Key result
Low plasmin-alpha2-antiplasmin complex plasma levels were associated with a fivefold increase in the relative risk of coronary re-events in survivors of myocardial infarction (RR 5.0; 95% CI 1.6-15.3; P=0.004).
Why the study?
Do low plasmin-alpha2-antiplasmin complex (PAP) plasma levels predict coronary re-events in survivors of myocardial infarction?
Cohort (n=200)
Do low plasmin-alpha2-antiplasmin complex (PAP) plasma levels predict coronary re-events in survivors of myocardial infarction?
Low plasma levels of plasmin-alpha2-antiplasmin complex (PAP) independently predict subsequent coronary events in survivors of myocardial infarction.
Answers are grounded in this paper and cite their sources.
Low PAP levels may flag higher re-event risk post-MI; leaves open whether measurement refines risk stratification.
Abnormalities of coagulation or fibrinolysis play a role in the pathogenesis of coronary artery disease (CAD). Elevated plasma levels of fibrinogen, von Willebrand factor antigen, plasminogen activator inhibitor-1 and tissue-type plasminogen activator were reported to be predictive for reinfarction and death in patients with CAD. We investigated the risk for coronary re-events associated with 18 hemostatic and fibrinolytic parameters in a prospective study including 200 survivors of myocardial infarction (MI). During a 2-year follow-up, 37 patients suffered one of the following predefined re-events: fatal MI (n = 2), non-fatal MI (n = 5), percutaneous transluminal coronary angioplasty (n = 17) or coronary artery bypass grafting (n = 13). Low plasmin-alpha2-antiplasmin complex (PAP) plasma levels were associated with an up to fivefold (95% confidence interval, 1.6-15.3) increase in relative risk. The association between decreasing PAP levels and coronary re-events remained significant (P = 0.004) after correction for possible confounders using multiple logistic regression analysis. Our data indicate low PAP plasma levels to be associated with subsequent coronary events in patients with a history of MI.
No takes yet. Share an insight, caveat, or question.
Redondo et al. (2001) conducted a cohort in Myocardial infarction (n=200). Low plasmin-alpha2-antiplasmin complex (PAP) plasma levels vs. Higher PAP plasma levels was evaluated on Coronary re-events (fatal MI, non-fatal MI, percutaneous transluminal coronary angioplasty, or coronary artery bypass grafting) (RR 5.0, 95% CI 1.6-15.3, p=0.004). Low plasmin-alpha2-antiplasmin complex plasma levels were associated with a fivefold increase in the relative risk of coronary re-events in survivors of myocardial infarction (RR 5.0; 95% CI 1.6-15.3; P=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: